Abeona Therapeutics Inc vs Corsair Gaming Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Corsair Gaming Inc trades at $12.94 (market cap $1.39B). The key difference: Corsair Gaming Inc is far larger — about 3.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CRSR | |
|---|---|---|
Market Cap | $421.19M | $1.39B |
Sector | Health | Technology |
52-Week High | $7.45 | $14.35 |
52-Week Low | $4.17 | $4.58 |
Enterprise Value | $276.10M | $1.38B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Corsair Gaming (CRSR) trades at $12.92, down 5.76% in the last session, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance, while recent acquisitions like Trak Racer and AI product launches aim to drive growth. However, the stock faces valuation concerns with a high P/E ratio of 41.39 and inconsistent profitability, as net income turned positive only in 2026 after previous losses.
The outlook is mixed: improved cash flow and strategic expansions support upside potential, but high valuation and competitive pressures pose risks. Analyst consensus is cautious with a $12.40 price target below the current price, suggesting limited near-term gains despite recent operational improvements.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →